Michael Shapiro to Anticholesteremic Agents
This is a "connection" page, showing publications Michael Shapiro has written about Anticholesteremic Agents.
Connection Strength
5.876
-
Shapiro MD, Taub PR, Louie MJ, Lei L, Ballantyne CM. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 Aug; 378:117182.
Score: 0.859
-
Shapiro MD. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving. Circulation. 2022 Oct 11; 146(15):1120-1122.
Score: 0.811
-
Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23; 28(8):816-822.
Score: 0.687
-
Mahmood T, Shapiro MD. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Curr Opin Cardiol. 2019 09; 34(5):519-525.
Score: 0.659
-
Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med. 2020 04; 30(3):179-185.
Score: 0.646
-
Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, Wojcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice. Circ Res. 2019 01 04; 124(1):32-37.
Score: 0.630
-
Shapiro MD, Miles J, Tavori H, Fazio S. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. Ann Intern Med. 2018 03 06; 168(5):376-379.
Score: 0.583
-
Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains. Curr Atheroscler Rep. 2015 Apr; 17(4):499.
Score: 0.485
-
Board C, Kelly MS, Shapiro MD, Dixon DL. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. J Cardiovasc Pharmacol. 2020 05; 75(5):410-420.
Score: 0.173
-
Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 02 19; 8(4):e010932.
Score: 0.159
-
Shapiro MD, Fazio S. Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. Nat Rev Cardiol. 2017 06; 14(6):319-320.
Score: 0.140
-
de Ferranti SD, Shrader P, Linton MF, Knowles JW, Hudgins LC, Benuck I, Kindt I, O'Brien EC, Peterson AL, Ahmad ZS, Clauss S, Duell PB, Shapiro MD, Wilemon K, Gidding SS, Neal W. Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. J Pediatr. 2021 02; 229:70-77.
Score: 0.044